Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q1 2024 · 10-Q
Revenue$94.67M$94.67M+24.2% vs Q1 2023 Net Income-$19.89M-$19.89MN/M vs Q1 2023 EPS Diluted-$0.22-$0.22N/M vs Q1 2023 Operating Income-$17,972,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,493,000N/M Margins · derivedOperating margin-19.0%+24.2 pt vs Q1 2023
Net margin-21.0%+18.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end